(REGN)—NVS’ RTH258 non-inferior to Eylea with less-frequent injections: https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients Detailed data at an upcoming medical conference.